| 生物靶向制剂与高T2型哮喘 |
| |
| 引用本文： | 何苗,王翎.生物靶向制剂与高T2型哮喘[J].安徽医药,2024,28(2):406-410. |
| |
| 作者姓名： | 何苗 王翎 |
| |
| 作者单位： | 苏州大学附属第一医院全科医学科，江苏苏州 215006 |
| |
| 基金项目： | 苏州市医学重点扶持学科( SZFCXK20211) |
| |
| 摘 要： | 哮喘是一种异质性疾病，约50%的哮喘病人存在2型炎症，T2哮喘主要由包括白细胞介素（IL）-4、IL-5和IL-13等T2细胞因子驱动的气道炎症引起，全球哮喘倡议（GINA）指南建议对T2炎症引起的严重哮喘病人使用生物制剂，当前和未来的生物疗法正在显著改变全球严重哮喘管理。这些新的治疗方案使得实施表型/内型特异性治疗成为可能。该文回顾了目前用于高T2型哮喘生物制剂的作用机制、功效和适应证，讨论了在这些生物制剂之间进行选择时的考虑因素。
|
| 关 键 词： | 哮喘 白细胞介素-4 白细胞介素-5 白细胞介素-13 生物制剂 高T2哮喘 生物标志物 靶向治疗 |
Targeted biological agents for T2-high asthma |
| |
| HE Miao,WANG Ling.Targeted biological agents for T2-high asthma[J].Anhui Medical and Pharmaceutical Journal,2024,28(2):406-410. |
| |
| Authors: | HE Miao WANG Ling |
| |
| Institution: | Department of General Medicine, The First Affiliated Hospital of Soochow University, Suzhou,Jiangsu215006, China |
| |
| Abstract: | Asthma is a heterogeneous disease. About 50% of patients with asthma have type 2 inflammation. T2 asthma is mainlycaused by airway inflammation driven by T2 cytokines, including interleukins IL-4, IL-5, IL-13,etc. The Global Initiative for Asthma(GINA) recommends the use of biological agents in patients with severe asthma caused by T2 inflammation. Current and future biologictherapies are remarkably changing the management of severe asthma globally. These new therapies make it possible to implement spe.cific phenotypes/endophenotypes treatments for asthma patients. This article reviews the mechanism, efficacy and indications of current biological agentsapplied to T2-high asthma, and discusses the factors considered when choosing among them. |
| |
| Keywords: | Asthma Interleukin-4 Interleukin-5 Interleukin-13 Biological agent T2-high asthma Biomarkers Targeted therapy |
|
| 点击此处可从《安徽医药》浏览原始摘要信息 |
| 点击此处可从《安徽医药》下载免费的PDF全文 |
